Chargement en cours...

Linaclotide: Promising IBS-C Efficacy in an Era of Provisional Study Endpoints

Recent disappointing developments in the pharmacotherapy of irritable bowel syndrome (IBS) have not dampened the enthusiasm surrounding linaclotide, a novel guanylate cyclase-C agonist for the management of constipation-predominant IBS (IBS-C). Two recent phase 3 studies reporting on a single, daily...

Description complète

Enregistré dans:
Détails bibliographiques
Auteur principal: Sayuk, Gregory S.
Format: Artigo
Langue:Inglês
Publié: 2012
Sujets:
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC3957218/
https://ncbi.nlm.nih.gov/pubmed/23160292
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/ajg.2012.325
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!